Overlooked and Undervalued: Why Bausch Health Companies Deserves Attention

2026-02-03 23:20:00 ET

Bausch Health Companies (NYSE: BHC) shares have struggled for many year, and 2026 is not currently off to a good start. Since the start of the year, Bausch Health has fallen by 17%. There are several substantive reasons behind this pullback.

For one, the pharmaceutical and medical device company experienced a major setback in minimizing its upcoming major patent cliff -- an event when a company's highest-grossing drug loses patent exclusivity.

The subsequent launch of generic alternatives following this patent exploration could impact Bausch's long-term strategy to unlock shareholder value. This plan entails growing the business while using cash flow to pay down debt, with ultimate plans to monetize a key "hidden asset."

Continue reading